Crispr Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Piper Jaffray Companies increased their Q1 2020 earnings per share estimates for shares of Crispr Therapeutics in a report released on Tuesday, November 26th, according to Zacks Investment Research. Piper Jaffray Companies analyst E. Tenthoff now anticipates that the company will earn ($1.20) per share for the quarter, up from their prior estimate of ($1.29). Piper Jaffray Companies has a “Buy” rating and a $104.00 price target on the stock. Piper Jaffray Companies also issued estimates for Crispr Therapeutics’ Q2 2020 earnings at ($1.30) EPS, Q3 2020 earnings at ($1.39) EPS, Q4 2020 earnings at ($1.49) EPS, FY2020 earnings at ($5.38) EPS, Q1 2021 earnings at ($1.65) EPS, Q2 2021 earnings at ($1.81) EPS, Q3 2021 earnings at ($1.88) EPS and FY2021 earnings at ($7.38) EPS.

Several other research firms also recently issued reports on CRSP. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Oppenheimer lifted their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, November 25th. Canaccord Genuity boosted their target price on Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a research note on Wednesday, November 20th. Finally, Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the stock. Crispr Therapeutics presently has a consensus rating of “Buy” and an average target price of $69.54.

Shares of CRSP stock traded up $2.92 during trading hours on Thursday, hitting $68.06. 1,025,775 shares of the company were exchanged, compared to its average volume of 714,849. The business has a 50 day moving average of $61.79 and a two-hundred day moving average of $49.31. The company has a market capitalization of $3.64 billion, a PE ratio of -19.78 and a beta of 3.30. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics has a 52 week low of $22.22 and a 52 week high of $74.00.

Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at $390,000. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock valued at $3,620,760 over the last three months. Insiders own 21.40% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nikko Asset Management Americas Inc. lifted its holdings in Crispr Therapeutics by 48.4% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after purchasing an additional 906,006 shares during the last quarter. ARK Investment Management LLC boosted its position in Crispr Therapeutics by 34.7% during the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after purchasing an additional 701,332 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Crispr Therapeutics by 19.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares during the period. Wells Fargo & Company MN boosted its position in Crispr Therapeutics by 23.9% during the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares during the period. Finally, Orbimed Advisors LLC acquired a new position in shares of Crispr Therapeutics in the third quarter valued at $21,167,000. 49.82% of the stock is owned by institutional investors.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: How does quantitative easing work?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.




Source link